We’re excited to announce this year’s finalists for the second annual 2021 BioBuzz Awards. These awards celebrate the people and companies across our regional community and their efforts and accomplishments to impact human health and build a stronger biotech community.
Cartesian Therapeutics to double footprint, headcount in Gaithersburg
Published on :Gaithersburg’s Cartesian Therapeutics Inc. is expanding its local footprint and initiating an aggressive hiring spree as the company bolsters its leadership team — and looks to get a cell therapy candidate through the clinic.
The biopharma, which already occupies about 4,500 square feet at 704 Quince Orchard Road, is taking over another 3,500 square feet adjacent to its existing space in the building, Dr. Murat Kalayoglu, president and CEO of Cartesian, told the Washington Business Journal.
The company declined to disclose the projected cost of the expansion, citing confidentiality reasons per its contract with Alexandria Real Estate Equities Inc. (NYSE: ARE), which in partnership with South Duvall — an affiliate of Rockville’s Scheer Partners — paid $6.9 million for the 80,000-square-foot office building in 2018. The building in the Gaithersburg biotech corridor is also home to a flurry of local players, including Novavax Inc. (NASDAQ: NVAX), miRecule Inc., VLP Therapeutics Inc. and others.
Cartesian Therapeutics Announces Clinical Responses in First Cohort of Phase 1b/2a Trial in Myasthenia Gravis
Published on :Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology, today announced clinical data from the first cohort of an ongoing Phase 1/2a clinical trial of Descartes-08 in patients with generalized Myasthenia Gravis (gMG). Descartes-08 is an mRNA-modified, autologous CAR T-cell product directed against B-Cell Maturation Antigen (BCMA).
Murat Kalayoglu, MD, PhD, President & CEO, Cartesian Therapeutics, Discusses New Frontline Therapy Treatment for Multiple Myeloma
Published on :Murat Kalayoglu, MD, PhD, President & CEO, Cartesian Therapeutics, Discusses New Frontline Therapy Treatment for Multiple Myeloma Cartesian Therapeutics, a biopharmaceutical company that specializes in mRNA-engineered cell therapy, recently announced [….]
BioHealth Capital Region Showcases Strengths of Cutting Edge Therapies
Published on :Biopharma and Life Science companies in the BioHealth Capital Region are known for their work with cutting edge technologies such as gene and cell therapies. Those strengths were on display at the 6th annual BioHealth Capital Region Forum.
21 Emerging Life Science Companies Fueling Maryland’s Biohealth Ecosystem
Published on :Maryland is the epicenter of biotech and life science innovation in the BioHealth Capital Region (BHCR). The state is home to a burgeoning life science ecosystem, including a rapidly growing cell and gene therapy industry, a robust and growing advanced biomanufacturing environment, and a deep network of leading research universities and critical government life science research entities.
After Leading a Dozen Startups Here is What Four Biotech Founders Had To Share About Their Success
Published on :Veteran biotech entrepreneurs discuss journey to success in their careers at the BioBuzz: CEO Talks event in the BioHealth Capital Region
First Car-T for an Autoimmune Disease Enters Clinic
Published on :First Car-T for an Autoimmune Disease Enters Clinic Maryland-Based Cartesian Therapeutics Initiates CAR-T Clinical Trial in Myasthenia Gravis Gaithersburg, MD, November 5, 2019 – see full press release Founded in [….]